Humanigen announces first patient dosed in phase 3 clinical study of lenzilumab in Covid-19
This article was originally published here
The primary goal of this Phase 3 randomized, double-blind, multicenter, placebo-controlled clinical trial is to determine if lenzilumab can help hospitalized patients with COVID-19 recover faster. As many
The post Humanigen announces first patient dosed in phase 3 clinical study of lenzilumab in Covid-19 appeared first on Pharmaceutical Business review.
Leave a Reply
Want to join the discussion?Feel free to contribute!